Tofacitinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dermatomyositis
Conditions
Dermatomyositis
Trial Timeline
Jan 1, 2017 → Sep 30, 2020
NCT ID
NCT03002649About Tofacitinib
Tofacitinib is a phase 1 stage product being developed by Pfizer for Dermatomyositis. The current trial status is completed. This product is registered under clinical trial identifier NCT03002649. Target conditions include Dermatomyositis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04624230 | Phase 3 | Active |
| NCT04721821 | Pre-clinical | Completed |
| NCT04424303 | Pre-clinical | Completed |
| NCT04338204 | Pre-clinical | Recruiting |
| NCT04412252 | Phase 2 | Withdrawn |
| NCT04175886 | Pre-clinical | Terminated |
| NCT03502616 | Phase 3 | Completed |
| NCT03387423 | Pre-clinical | Completed |
| NCT03288324 | Phase 1/2 | Completed |
| NCT03002649 | Phase 1 | Completed |
| NCT06688838 | Pre-clinical | Recruiting |
Competing Products
14 competing products in Dermatomyositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| M5049 high dose + Placebo | Merck | Phase 2 | 52 |
| BAF312 + Placebo | Novartis | Phase 2 | 52 |
| MEDI7734 + Placebo | Amgen | Phase 1 | 32 |
| Etanercept + Placebo | Amgen | Phase 1 | 32 |
| Dazukibart | Pfizer | Phase 3 | 76 |
| Anti-Beta Interferon (PF-06823859) | Pfizer | Phase 2 | 51 |
| PF-06823859 low + Placebo Arm + PF-06823859 high | Pfizer | Phase 2 | 51 |
| Emapalumab | Swedish Orphan Biovitrum | Phase 2 | 51 |
| human immunoglobulin G + Placebo | CSL | Phase 3 | 76 |
| Empasiprubart IV | Argenx | Phase 2 | 49 |
| GLPG3667 + Placebo | Galapagos | Phase 2 | 47 |
| Lenabasum 20 mg + Lenabasum 5 mg + Placebo | Corbus Pharmaceuticals | Phase 3 | 69 |
| JBT-101 + Placebo | Corbus Pharmaceuticals | Phase 2 | 44 |